Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer.
Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussein M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. Riely GJ, et al. Among authors: gelsomino f. Future Oncol. 2024;20(16):1047-1055. doi: 10.2217/fon-2023-0859. Epub 2024 Feb 15. Future Oncol. 2024. PMID: 38357801 Free PMC article.
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.
Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussain M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. Riely GJ, et al. Among authors: gelsomino f. J Clin Oncol. 2023 Jul 20;41(21):3700-3711. doi: 10.1200/JCO.23.00774. Epub 2023 Jun 4. J Clin Oncol. 2023. PMID: 37270692 Clinical Trial.
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.
Di Federico A, Angelicola S, Frascino M, Siracusa I, Bisanti B, Ruzzi F, Semprini MS, De Jonge H, De Giglio A, Sperandi F, Brocchi S, Melotti B, Giunchi F, Gruppioni E, Altimari A, Lollini PL, Ardizzoni A, Palladini A, Gelsomino F. Di Federico A, et al. Among authors: gelsomino f. JCO Precis Oncol. 2024 Dec;8:e2400240. doi: 10.1200/PO.24.00240. Epub 2024 Dec 5. JCO Precis Oncol. 2024. PMID: 39637338 Free PMC article.
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Andrini E, Lamberti G, Mazzoni F, Riccardi F, Bonetti A, Follador A, Artioli F, Genova C, Barbieri F, Frassoldati A, Brighenti M, Colantonio I, Pasello G, Ficorella C, Cinieri S, Tiseo M, Gelsomino F, Tognetto M, Rihawi K, Ardizzoni A. Andrini E, et al. Among authors: gelsomino f. Future Oncol. 2022 Mar;18(7):771-779. doi: 10.2217/fon-2021-1027. Epub 2022 Jan 24. Future Oncol. 2022. PMID: 35068173
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.
Mosca M, Conci N, Di Federico A, Tateo V, Favorito V, Zappi A, Gelsomino F, De Giglio A. Mosca M, et al. Among authors: gelsomino f. JCO Precis Oncol. 2023 May;7:e2300073. doi: 10.1200/PO.23.00073. JCO Precis Oncol. 2023. PMID: 37262392 Review.
206 results